Several studies have indicated that PP2A inactivation is a key molecular pathogenetic event in cancer and AD and that pharmacological strategies to re-activate PP2A might unfold new therapeutic opportunities, as reviewed [18,53,54,109,118,119,126–132]. The gene discussed is PTPA; the disease is cancer.